◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
technica.bio / ADC Landscape / BMS / Eisai
ADC Landscape

BMS / Eisai

FRα · NSCLC, ovarian, endometrial

Phase 2Antibody–Drug Conjugates
Target
FRα
Payload
Eribulin
Payload class
Tubulin inhibitor
Linker
Cleavable (mc-vc-PABC)
Indication
NSCLC, ovarian, endometrial
Phase
Phase 2
Partner
Eisai

Overview

Uses Eisai's marketed chemo eribulin as the ADC payload — a rare repurposing of a clinically validated cytotoxic into a targeted conjugate.

Technology

BMS / Eisai works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.

Read the Antibody–Drug Conjugates brief →

Related companies

Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.